

DR GAURAV M PARMAR (Orcid ID : 0000-0002-6170-4066)

Article type : Original Research Article

Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage

Running head: Influence of age on warfarin

*Aditi Shendre,¹ *Gaurav M. Parmar,² Chrisly Dillon,³ T. Mark Beasley,⁴ Nita A. Limdi³

*** These authors contributed equally**

¹ Richard M. Fairbanks School of Public Health, Indianapolis University Purdue University

Indianapolis, Indianapolis, Indiana

² Division of Vascular Surgery and Endovascular Therapy, University of Alabama at

Birmingham, Birmingham, Alabama

³ Department of Neurology, School of Medicine, University of Alabama at Birmingham,

Birmingham, Alabama

⁴ Department of Biostatistics, School of Public health, University of Alabama at

Birmingham,

Birmingham, Alabama

Corresponding Author:

Nita A. Limdi

Department of Neurology, University of Alabama at Birmingham

1235 Jefferson Tower, 625 19th Street South, Birmingham AL 35294-0021

Email: nlimdi@uabmc.edu

Phone: (205) 934-4385

This is the author's manuscript of the article published in final edited form as:

Shendre, A., Parmar, G. M., Dillon, C., Beasley, T. M. and Limdi, N. A. (2018), Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage. *Pharmacotherapy*. Accepted Author Manuscript. <http://dx.doi.org/10.1002/phar.2089>

Conflict of interest: NL consults for Admera Health but that affiliation is not related to the contents of this study. The rest of the authors listed above certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Keywords:

Age, warfarin dose, percent time in target range (PTTR), major hemorrhage

Sources of Funding: This work was supported in part by grants from the National Heart Lung and Blood Institute (RO1HL092173; 1K24HL133373), National Institute of General Medical Sciences (R01GM081488) and the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program (UL1TR000165).

Abstract

Objective: We assessed the influence of age on warfarin dose, percent time in target range (PTTR), and risk of major hemorrhage.

Design: Warfarin users recruited into a large prospective inception cohort study were categorized into three age groups: young (<50 years), middle-aged (50 -70 years), and elderly (>70 years). The influence of age on warfarin dose and PTTR was assessed using regression analysis and risk of major hemorrhage was assessed using the proportional hazards (PH) analysis. Models were adjusted for demographic, clinical and genetic factors.

Setting: Two outpatient anticoagulation clinics

Participants: 1498 anticoagulated patients

This article is protected by copyright. All rights reserved.

Outcomes: Warfarin dose (mg/day), PTTR, major hemorrhage

Results: Of the 1498 patients, 22.8% were young, 44.1% were middle-aged, and 33.1% were elderly. After accounting for clinical and genetic factors, compared to young warfarin users, warfarin dose requirements were 10.6% lower among the middle-aged and an additional 10.6% lower for the elderly. Compared to young patients, middle-aged and elderly patients spent more time in target INR range ($p<0.0001$), despite having fewer INR assessments ($p<0.0001$). Compared to young warfarin users, absolute risk for hemorrhage was marginally higher among middle-aged ($p=0.08$) and significantly higher among the elderly ($p=0.016$). Compared to young warfarin users, after adjustment, the relative risk of hemorrhage increased by 31% for each age category ($p=0.026$).

Conclusions: In a real-world setting, despite achieving better anticoagulation control, elderly patients had a higher risk of major hemorrhagic events. As the population ages and the candidacy for oral anticoagulation increases, strategies that mitigate the elevated risk of hemorrhage need to be identified.

Introduction

Oral anticoagulants are the main treatment modality for decreasing the risk of venous thromboembolism and thromboembolic events associated with atrial fibrillation.¹ Despite the introduction of non-vitamin K antagonists (DOACs), warfarin remains the most widely used oral anticoagulant in the US.^{2,3} Warfarin dosing has remained challenging because of its pronounced inter-individual variability, narrow therapeutic index, drug and dietary interactions,⁴ and potential for over-anticoagulation leading to hemorrhagic complications.⁵⁻⁷ Thus, despite being efficacious, warfarin is underutilized,^{8,9} due in part to fear of bleeding episodes.¹⁰ Anticoagulation related bleeding is a frequent cause of adverse drug related hospitalizations in the US.¹¹

Increasing age is an important predictor of dose and a non-modifiable risk factor for hemorrhage.¹²⁻¹⁵ As the population ages, the need for anticoagulation is expected to increase with the rise in age-related comorbidities. For instance, the prevalence of atrial fibrillation (AF), the most common dysrhythmia, increases with age and is expected to reach 12.1 million by 2030.¹⁶⁻¹⁸ Additionally, patients with AF are five times more likely to experience an ischemic stroke and twice as likely to die compared to patients without AF.^{19, 20} Therefore, the need for safe and effective anticoagulation in an aging population is of paramount importance. To this end, we examined the effect of age on dose, anticoagulation control, and major hemorrhagic events in warfarin users after accounting for clinical and genetic variables.

Methods

Study Population

Participants (≥ 20 years old) initiating warfarin with the target international normalized ratio (INR) of 2.0-3.0 were enrolled at the beginning of treatment in an inception cohort under the approval of the Institutional Review Boards of the University of Alabama at Birmingham and Emory University. Patients requiring a target INR of 2.5-3.5 (e.g. mechanical heart valves) were excluded.^{21, 22}

Clinical and Genetic Variables

Patients managed at two oral anticoagulant clinics were approached and consented for enrollment in the study. Patient history was collected through a structured interview form and included information on demographics, indications for therapy, comorbidities, and medications as previously reported.²¹⁻²³ Information on factors related to lifestyle and socio-economic status including smoking, alcohol use, physical activity, dietary vitamin K intake, education, annual household income, and medical insurance was also collected. Medical records were reviewed to verify the medical history of the patients.

Follow-up included monthly visits for up to two years from initiation of therapy. Information on factors that affect warfarin response were collected during these visits, and included INR, concurrent medications, dietary vitamin K intake, alcohol use, and physical activity. Medication information was verified by medical record review as before, with emphasis on drugs that alter warfarin response, including non-steroidal anti-inflammatory drugs, antiplatelet agents, and *CYP2C9* inhibitors, inducers, or substrates.

In addition to clinical data, patients were genotyped for warfarin-specific polymorphisms.^{21, 22} Blood samples were collected during the enrollment visit, and DNA extracted using the Gentra PureGene system (Gentra Sys, Inc. Minneapolis, MN). *VKORC1* (rs9923231), *CYP2C9* [*2 (rs1799853), *3 (rs1057910)], *CYP4F2* (rs2108622), African American specific *CYP2C9* Single Nucleotide Polymorphisms (SNPs) [*5 (rs28371686), *6 (rs9332131), *11 (rs28371685)], and the *CYP2C* SNP rs12777823 were genotyped.²¹⁻²⁶

Outcome definitions

Warfarin dose (mg/day; log transformed to attain normality) was defined as the average maintenance dose after the attainment of three consecutive INRs in target range measured at least 2 weeks apart, as previously defined.^{24, 25, 27, 28}

Proportion of time spent in target range (PTTR) and quality of anticoagulation control: For each patient, PTTR was calculated as the percentage of interpolated INR values within the target range of 2.0–3.0 after attainment of first INR in target range using the Rosendaal linear interpolation method.²⁹ We also present proportion of time spent below (PTBR) and above (PTAR) target range.

Accepted Article

Because PTTR is a recognized risk factor for hemorrhage, we categorized patients' quality of anticoagulation control based on cumulative PTTR in two ways. First, we considered PTTR $\geq 60\%$ (vs. $<60\%$) because this has been evaluated as a predictor of hemorrhage in warfarin users in recent clinical trials and has also been included in the recently proposed HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR (defined as PTTR $<60\%$), Elderly, Drug consumption/alcohol abuse) score.³⁰ Second, as the effectiveness of warfarin compared to the newer oral anticoagulants is related to the level of PTTR achieved, we also categorized PTTR as poor anticoagulation control (PTTR $<60\%$), good control ($60 \leq \text{PTTR} < 70$), and excellent control (PTTR ≥ 70).³¹⁻³⁴

Major Hemorrhage: As previously defined,³⁵ major hemorrhages included fatal bleeding; and/or symptomatic bleeding in a critical area or organ, such as intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular, or pericardial, or intramuscular with compartment syndrome; and/or bleeding with a fall in hemoglobin level of ≥ 2 gm/dL, or leading to transfusion of ≥ 2 units of whole blood or red cells. As the focus of this manuscript was to evaluate the association of age on risk of major hemorrhages, minor hemorrhages (mild nosebleeds, microscopic hematuria, mild bruising, and mild hemorrhoidal bleeding) were not included in the analysis. During the 2-year follow-up, for all major hemorrhagic complications, the complication site (e.g. endoscopy of gastrointestinal tract), severity of the event (e.g. requiring transfusion, surgical intervention), and laboratory findings (e.g. INR, hemoglobin/hematocrit) at the time of the event were objectively documented. Isolated sub-therapeutic or supra-therapeutic INRs in the absence of evidence of bleeding were not classified as events. The Alabama Center for Health Statistics was queried to verify cause of death for all deceased to ensure inclusion of deaths due to hemorrhagic complications. All

Accepted Article

complications were adjudicated independently by the Medical Director of the Anticoagulation Clinic. Only medically documented, adjudicated events were included in the analyses, as previously reported.^{27, 36-38}

Statistical Analyses

Analysis of variance was used to assess group differences for continuous variables and chi-square for categorical variables. All SNPs were tested for the Hardy-Weinberg Equilibrium assumption by calculating the allele as well as genotype frequencies and using a chi-square exact test.

First, we evaluated the univariate association of age with warfarin dose, PTTR, and risk of hemorrhage. These results informed the age-categorization for subsequent adjusted analyses as young (<50), middle-aged (50-70) and elderly (>70). We then evaluated the effect of age (young, middle-aged, elderly) on warfarin dose and PTTR using multivariable linear regression analysis. The influence of age on the risk of major hemorrhage was assessed using the counting process format in the proportional hazards (PH) model. The models were adjusted for demographic [i.e. gender, race, body mass index (BMI)], lifestyle (i.e. smoking), clinical comorbid conditions [i.e. kidney impairment (categorized as estimated glomerular filtration rate eGFR >60, 30-59, <30ml/min/1.73 m²)], medication use (i.e. antiplatelet), or genetic (i.e. *CYP2C9*, *CYP4F2*, *VKORC1* and rs12777823) factors. We included factors that showed significant differences in prevalence by age in our cohort and retained these factors in the model at a nominal p-value of ≤ 0.2 . All analyses were performed using SAS version 9.3 at a non-directional alpha level of 0.05.

Role of the funding source

The study was funded by the National Institutes of Health, but the funders had no role in the study design, data collection, data analysis, interpretation of results, or writing of this manuscript.

Results

Of the 1498 patients (48% women, 44% African American) included in the analysis, 341 (23%) were below the age of 50 years (young), 661 (44%) were between the ages of 50 and 70 years (middle-aged) and 496 (33%) were more than 70 years of age (elderly).

Participant characteristics by age groups are shown in **Table 1**.

Compared to young warfarin users, the middle-aged and elderly patients had lower warfarin dose requirements ($p<0.0001$) and lower eGFR ($p<0.0001$). When compared to younger and middle-aged groups, the elderly group consisted of a significantly higher proportion of women ($p=0.048$) and European Americans ($p<0.0001$), and were more likely to be on warfarin due to atrial fibrillation ($p<0.0001$). The younger patients were more likely to be African American and be on warfarin for venous thromboembolism ($p<0.0001$). The prevalence of hypertension ($p<0.0001$), hyperlipidemia ($p<0.0001$), diabetes ($p<0.0001$), and heart failure ($p=0.0026$) increased with age. The elderly had the highest prevalence of stage 3 chronic kidney disease (CKD) (eGFR 30 -59ml/min/1.73m²) and the lowest prevalence of end stage renal disease (eGFR<30 ml/min/1.73m²). Similarly, the concurrent use of statins ($p<0.0001$), antiplatelet agents ($p<0.0001$), and amiodarone ($p=0.001$) was highest among the elderly. The assumption of Hardy Weinberg Equilibrium was met for all SNPs ($p>0.20$). The prevalence of genetic factors known to influence warfarin response did not vary by age group

except for the *VKORC1* ($p<0.0001$) and *CYP2C9*3* variants ($p=0.01$), which were more prevalent in the elderly.

After accounting for clinical and genetic factors, compared to young patients, warfarin dose requirements were 10.6% lower among the middle-aged and an additional 10.6% lower for the elderly patients. Gender did not influence warfarin dose requirements. Warfarin dose requirements were lower among patients possessing *CYP2C9*, *VKORC1* and rs12777823 variant, among African Americans, in patients with CKD, congestive heart failure (CHF) and those on concurrent amiodarone therapy. On the other hand, higher BMI, venous thromboembolism and possession of the *CYP4F2* variant were associated with higher warfarin dose requirements. The final dosing algorithm by age after incorporating clinical and genetic factors is presented in **Table 2**.

Overall PTTR in the study cohort was 52.4% ($\pm 22.5\%$). Young patients spent more time below range (PTBR, $p<0.0001$) compared to the middle-aged and elderly (**Table 3, Figure 1a**). Compared to young patients, middle-aged and elderly patients spent more time in target INR range ($p<0.0001$), despite having fewer INR assessments per month (1.78 ± 1.52 vs. 1.35 ± 1.19 vs. 1.24 ± 1.74 visit/month, $p<0.0001$). Patients achieving a PTTR $\geq 60\%$ over the treatment period are considered to have good anticoagulation control and those achieving a PTTR $\geq 70\%$ are considered to have excellent anticoagulation control. Young warfarin users were less likely to achieve these metrics for anticoagulation control compared to the middle-aged ($p<0.0001$) and elderly ($p<0.0001$) warfarin users (**Table 3, Figure 1b**).

Over 2050 person-years of follow-up, 173 major hemorrhagic events were encountered [incidence rate (IR): 8.44; 95% CI: 7.25-9.77]. Major hemorrhages by site included gastrointestinal ($n=104$), genitourinary ($n=22$), retroperitoneal ($n=7$), intracranial

Accepted Article

bleeds (n=15), hemoptysis (n=5), and hematomas (n=20). Incidence rates were lowest in the young warfarin users and highest among the elderly (**Table 3**). Compared to young warfarin users, the incidence rate ratio (IRR) of hemorrhage was marginally higher among middle-aged (IRR: 1.5; 95% CI 0.95-2.56; p=0.08) and significantly higher among the elderly (IRR: 1.8; 95% CI 1.12-3.0; p=0.016).

After adjusting for race, gender, BMI, hypertension, chronic kidney disease, PTTR (<60 vs. ≥60%), genetic factors, concurrent antiplatelet, amiodarone and statin therapy, the risk of hemorrhage increased by 31% for each age category (HR= 1.31 95% CI 1.03-1.66; p=0.026; **Figure 1c**) when compared to young warfarin users. In addition to older age, African American race (HR= 1.49 95% CI 1.02-2.17; p=0.04), concomitant antiplatelet therapy (HR= 1.64; 95% CI 1.14-2.36; p=0.008), hypertension (HR= 1.70; 95% CI 1.07-2.71; p=0.025), CKD (HR= 1.49; 95% CI 1.15-1.96; p<0.0001), PTTR<60% (HR= 2.27; 95% CI 1.51-3.42; p<0.0001), and possession of *CYP2C9*3* variant (HR=1.7; 95% CI 1.0- 2.9; p=0.05) were associated with an increased risk of hemorrhage.

Discussion

We present a comprehensive look at warfarin response among young (<50), middle-aged (50-70), and elderly (>70) warfarin users from a large prospective cohort study. We demonstrate that middle-aged patients need a 10% warfarin dose reduction and the elderly need an additional 10% warfarin dose reduction after accounting for clinical and genetic factors. Assessment of anticoagulation control (PTTR) showed that middle-aged and elderly patients have better anticoagulation control as compared to young warfarin users, and a higher proportion of these patients also achieve good (PTTR>60%) and excellent control (PTTR>70%). Furthermore, evaluation of the age-hemorrhage association indicated that elderly patients have a higher risk of major hemorrhage despite achieving better anticoagulation control.

Our study found a significant inverse association between age and warfarin dose, a finding that is consistent with existing literature.¹²⁻¹⁵ Warfarin dose reductions in prior studies have ranged from 8% to 21% per decade of life, whereas evaluation of age on a continuous scale has been shown to result in a weekly warfarin dose decrease of 0.4 mg per year of aging.¹²⁻¹⁵ Thus, older patients are more sensitive to warfarin compared to younger patients. Age related changes in drug response are multifactorial with decline in clearance, albumin binding, or renal excretion contributing to pharmacokinetic changes.³⁸⁻⁴⁰ Moreover, the increase in comorbid conditions and concomitant medication use in the elderly may influence warfarin response in complex ways through drug-drug and drug-disease interactions. This is illustrated by the multitude of factors that influence warfarin dosing, several of which are now included in the warfarin dosing algorithm.

Several factors significantly associated with warfarin dose in the current study are also part of the commonly used warfarin dosing algorithm listed above and have been established as important predictors of warfarin dose and response. Our own research group has previously reported on the associations of kidney function,²⁵ left ventricular systolic dysfunction,⁴¹ and the *CYP2C9*,^{21,22} *VKORC1*,^{22,23} and *CYP4F2*²⁷ variants with warfarin dose. We also recently evaluated the differential effect of self-reported race on warfarin, reporting on the variable effect of genetic and non-genetic factors on warfarin dose and hemorrhage by race.^{28,36} However, the effect of age on warfarin dose was similar across race groups in our study.³²

Age is also an important predictor of bleeding outcomes among warfarin users, and has been incorporated into several bleeding risk scores.^{30,42-44} However, comparison of the different scores show variability in classification across risk categories and only modest improvements in the ability to predict bleeding outcomes.^{45,46} Moreover, the age cut-off across these models are not consistent, making it difficult to establish a fixed age threshold

for assessing bleeding risk. The recent evaluation by Senoo et al. demonstrated that the HAS-BLED score performed better compared to the ATRIA or ORBIT scores because it incorporates PTTR.⁵⁰ A significant body of evidence exists which supports that poor anticoagulation control (PTTR<60%) is a predictor for hemorrhage among warfarin users.³¹⁻³⁴ Moreover, PTTR≥60% is widely recognized as the accepted quality metric for anticoagulation management services and is incorporated into risk prediction rules. The consistency of the influence of PTTR on risk of hemorrhage was also demonstrated in the recent DOAC clinical trials.^{34,47} For instance, compared to dabigatran (150 mg dose), the risk of hemorrhage was higher for warfarin users with PTTR <57%, similar among warfarin users with PTTR 57-72%, and lower among those with PTTR>72%.³⁴ In our study, older patients had significantly higher PTTR compared to younger patients but also had a higher risk of major hemorrhagic events despite attaining better anticoagulation control. Sanden et al. demonstrated that at very high PTTR (>70), where almost all patients have achieved therapeutic INR of 2.0-3.0, PTTR was not correlated to warfarin-related complications in patients with AF.⁴⁸ In this scenario, it is possible that factors other than PTTR such as poor hypertension control may be responsible for the high hemorrhagic risk. Another possible explanation may be age-related frailty where the deterioration in normal bodily functions play a role in precipitating adverse outcomes.^{49,50} Although aiming for a lower INR target range (1.6 to 2.6) in patients over the age of 70 may reduce the bleeding risk,^{51,52} it may also limit effectiveness.⁵³ Based on current evidence, the benefits of warfarin therapy (INR 2-3) still outweigh the risks even in elderly patients.^{8,54}

Although this is a large prospective inception cohort study, we recognize its limitations. It was neither feasible nor possible to control for all potential confounders such as over-the-counter medication use, episodic use of antibiotics, dietary vitamin K intake, rare genetic variants, and gene-

gene, gene-environmental interactions. Given the efficacy of warfarin, the incidence of thromboembolic events among patients on warfarin in our cohort was low. As a result, we were unable to assess the benefit vs. risk of warfarin across the three age categories. However, anticoagulation control can serve as a practical surrogate for the actual thromboembolic events as it is always the goal for any anticoagulation therapy to attain target INR. All patients in our study were able to achieve a target INR of 2.0-3.0, however, this prevented us from assessing whether a lower INR range would result in a lower risk of hemorrhage. Finally, as in all observational studies, caution in ascribing the observed effects as causal is prudent.

Conclusion

Despite achieving better anticoagulation control, elderly patients on warfarin had a higher risk of major hemorrhagic events as compared to younger patients. Strategies to mitigate the hemorrhagic risk while maintaining the risk reduction in thromboembolic events are needed. As the population ages and the candidacy for oral anticoagulation increases, identifying reliable strategies that enable protection against adverse bleeding events would be impactful.

Acknowledgements

We are grateful to all the patients that participated in the study. We thank our research nurses for their untiring efforts with patient recruitment, and the medical faculty and staff of the Anticoagulation Clinic for their help with identification of potential participants.

This study has contributed samples to the NINDS Human Genetics Resource Center DNA and Cell Line Repository (<http://ccr.coriell.org/ninds>), NINDS Repository sample numbers corresponding to the samples used are ND04466, ND04556, ND04604, ND04605, ND04626, ND04869, ND04907, ND04934, ND04951, ND05036, ND05108, ND05175, ND05176, ND05239, ND05605, ND05606, ND05701, ND05702, ND05735, ND06147, ND06207, ND06385, ND06424, ND06480, ND06706,

ND06814, ND06871, ND06983, ND07057, ND07234, ND07304, ND07494, ND07602, ND07711,
ND07712, ND08065, ND08596, ND08864, ND08932, ND09079, ND09172, ND09760, ND09761,
ND09809.

References

1. Writing Group M, Mozaffarian D, Benjamin EJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. *Circulation* 2016;4:e38-360.
2. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in Ambulatory Oral Anticoagulant Use. *The American journal of medicine* 2015;12:1300-5 e2.
3. Hsu JC, Maddox TM, Kennedy KF, et al. Oral Anticoagulant Therapy Prescription in Patients With Atrial Fibrillation Across the Spectrum of Stroke Risk: Insights From the NCDR PINNACLE Registry. *JAMA Cardiol* 2016;1:55-62.
4. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. *Arch Intern Med* 2005;10:1095-106.
5. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;2 Suppl:e44S-e88S.
6. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008;6 Suppl:257S-98S.
7. White PJ. Patient factors that influence warfarin dose response. *Journal of pharmacy practice* 2010;3:194-204.
8. Baczek VL, Chen WT, Kluger J, Coleman CI. Predictors of warfarin use in atrial fibrillation in the United States: a systematic review and meta-analysis. *BMC Fam Pract* 2012;1:5.
9. Waldo AL, Becker RC, Tapson VF, Colgan KJ, Committee NS. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. *J Am Coll Cardiol* 2005;9:1729-36.
10. Sen S, Dahlberg KW. Physician's fear of anticoagulant therapy in nonvalvular atrial fibrillation. *Am J Med Sci* 2014;6:513-21.
11. Shehab N, Lovegrove MC, Geller AI, Rose KO, Weidle NJ, Budnitz DS. US Emergency Department Visits for Outpatient Adverse Drug Events, 2013-2014. *Jama* 2016;20:2115-25.
12. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. *Ann Pharmacother* 2002;10:1512-7.
13. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. *Thromb Haemost* 2004;1:87-94.
14. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. *Ann Intern Med* 1992;11:901-4.
15. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. *Chest* 2005;6:2049-56.
16. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation* 2004;9:1042-6.
17. Staerk L, Sherer JA, Ko D, Benjamin EJ, Helm RH. Atrial Fibrillation: Epidemiology, Pathophysiology, and Clinical Outcomes. *Circ Res* 2017;9:1501-17.

18. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. *Am J Cardiol* 2013;8:1142-7.
19. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. *Stroke* 1996;10:1760-4.
20. Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. *Eur Heart J* 2004;19:1734-40.
21. Limdi N, Goldstein J, Blaisdell J, Beasley T, Rivers C, Acton R. Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. *Per Med* 2007;2:157-69.
22. Limdi NA, Arnett DK, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. *Pharmacogenomics* 2008;5:511-26.
23. Limdi NA, Beasley TM, Crowley MR, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. *Pharmacogenomics* 2008;10:1445-58.
24. International Warfarin Pharmacogenetics C, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. *N Engl J Med* 2009;8:753-64.
25. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. *Am J Kidney Dis* 2010;5:823-31.
26. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. *Lancet* 2013;9894:790-6.
27. Shendre A, Brown TM, Liu N, et al. Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. *Pharmacotherapy* 2016;3:263-72.
28. Limdi NA, Brown TM, Yan Q, et al. Race influences warfarin dose changes associated with genetic factors. *Blood* 2015;4:539-45.
29. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. *Thromb Haemost* 1993;3:236-9.
30. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. *J Am Coll Cardiol* 2011;2:173-80.
31. Gallego P, Vilchez JA, Lane DA. Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range. *Circulation* 2013;22:2163-5.
32. Gallego P, Roldan V, Marin F, et al. SAME-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. *The American journal of medicine* 2014;11:1083-8.
33. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. *Circulation* 2008;20:2029-37.
34. Wallentin L, Yusuf S, Ezekowitz M, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. *Lancet* 2010;975 - 83.
35. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost* 2005;4:692-4.
36. Limdi NA, Brown TM, Shendre A, Liu N, Hill CE, Beasley TM. Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. *Pharmacogenet Genomics* 2017;10:347-55.
37. Shendre A, Beasley TM, Brown TM, Hill CE, Arnett DK, Limdi NA. Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications. *Pharmacotherapy* 2014;6:545-54.

38. Limdi MA, Crowley MR, Beasley TM, Limdi NA, Allon M. Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study. *Am J Kidney Dis* 2013;2:354-7.
39. Crooks J, O'Malley K, Stevenson IH. Pharmacokinetics in the elderly. *Clin Pharmacokinet* 1976;4:280-96.
40. Jensen AB, Palmer KA, Boomsma JJ, Pedersen BV. Varying degrees of *Apis mellifera ligustica* introgression in protected populations of the black honeybee, *Apis mellifera mellifera*, in northwest Europe. *Mol Ecol* 2005;1:93-106.
41. Ather S, Shendre A, Beasley TM, et al. Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin. *Am J Cardiol* 2016;2:232-6.
42. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. *J Am Coll Cardiol* 2011;4:395-401.
43. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). *Am Heart J* 2006;3:713-9.
44. Shireman TI, Mahnken JD, Howard PA, Kresowik TF, Hou Q, Ellerbeck EF. Development of a contemporary bleeding risk model for elderly warfarin recipients. *Chest* 2006;5:1390-6.
45. Burgess S, Crown N, Louzada ML, Dresser G, Kim RB, Lazo-Langner A. Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. *J Thromb Haemost* 2013;9:1647-54.
46. Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. *Am J Med* 2016;6:600-7.
47. Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. *Circulation* 2013;22:2166-76.
48. Sanden P, Renlund H, Svensson PJ, Sjalander A. Warfarin treatment complications do not correlate to cTTR when above 70. *Thromb Res* 2015;6:1185-9.
49. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet* 2013;9868:752-62.
50. Nguyen TN, Morel-Kopp MC, Pepperell D, Cumming RG, Hilmer SN, Ward CM. The impact of frailty on coagulation and responses to warfarin in acute older hospitalised patients with atrial fibrillation: a pilot study. *Aging Clin Exp Res* 2017;6:1129-38.
51. Kodani E, Atarashi H, Inoue H, et al. Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry. *J Stroke Cerebrovasc Dis* 2016;3:585-99.
52. Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. *Intern Med* 2001;12:1183-8.
53. Fang MC, Chang Y, Hylek EM, et al. Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation. *Ann Intern Med* 2004;10:745-52.
54. Bajorek B. A review of the safety of anticoagulants in older people using the medicines management pathway: weighing the benefits against the risks. *Ther Adv Drug Saf* 2011;2:45-58.

Table 1. Characteristics of the participants categorized by age

Footnote to table 1: SD: Standard Deviation

^aAll eGFR are based on National Kidney Foundation staging using the Modification of Diet in Renal Disease Study equation. Patients were categorized into 3 categories: GFR ≥ 60 (no CKD or mild CKD stage 1 and 2), GFR=30-59 (moderate CKD; stage 3) and GFR<30 (severe CKD; stage 4 and 5).

^bStatins included any of the HMG-COA reductase inhibitors.

^cConcurrent antiplatelet agents included aspirin, clopidogrel, and dipyridamole as mono or dual therapy.

^dGenotype information was not available in 93 patients for *CYP2C9*, 45 patients for *VKORC1*, 197 for *CYP4F2* and 198 for rs12777823 as these samples had not been genotyped. The *VKORC1* variant (-1639 C>T) includes 'TT or CT', *CYP4F2* variant includes 'AG or AA', and rs12777823 variant includes 'AG or GG'.

Table 2. Warfarin dose requirements by age (<50, 50-70, and >70 years) after accounting for clinical and genetic factors

Footnote to table 2: CI: confidence intervals, BMI: Body Mass Index

^aThe referent is a white male, 50 years or younger with BMI centered at 25 kg/m², without chronic kidney disease, venous thromboembolism or heart failure (left ventricular ejection fraction <55%), not on concurrent Amiodarone or statin therapy, with wild-type genotype for *CYP2C9*, *VKORC1*, *CYP4F2*, and rs12777823.

Table 3. Influence of age (<50, 50-70, and >70 years) on indices of anticoagulation control, and incidence of hemorrhage

Footnote to table 3: PTBR: Percent Time spent Below target INR Range, PTTR: Percent Time spent in Target INR Range, PTAR: Percent Time spent Above Target INR Range, CI: confidence intervals.

Table 1: Characteristics of the participants categorized by age

Characteristics	Age < 50	Age 50-70	Age >70
	n=341	n=661	n=496
	Mean ± SD	Mean ± SD	Mean ± SD
Mean Age	38.6 ± 8.1	60.0 ± 5.7	77.8 ± 5.6
Body mass index (BMI)	30.8 ± 8.5	31.3 ± 8.0	28.3 ± 6.1
Hematocrit, %	36.7 ± 13.3	37.1 ± 6.7	37.2 ± 6.5
Glomerular filtration rate (eGFR)	80.1 ± 38.2	67.5 ± 28.2	61.1 ± 21.6
Dose (mg/day)	6.8 ± 2.8	5.7 ± 2.4	4.6 ± 2.0
	N (%)	N (%)	
Female	172 (50.4%)	297 (44.9%)	257 (51.8%)
Race			
European American	138 (40.5%)	353 (53.4%)	337 (67.9%)
African American	197 (57.8%)	302 (45.9%)	156 (31.5%)
Other	6 (1.7%)	6 (0.7%)	3 (0.6%)
Indication for Warfarin therapy			
Venous thromboembolism	231 (67.7%)	283 (42.8%)	140 (28.2%)
Atrial Fibrillation	38 (11.1%)	267 (40.4%)	315 (63.5%)
Stroke / Transient Ischaemic Attack	21 (6.2%)	33 (5.0%)	25 (5.0%)
Other	51 (17.9%)	77 (11.6%)	15 (3.0%)
Comorbid conditions			
Hypertension	146 (44.4%)	470 (71.5%)	376 (76.0%)
Hyperlipidemia	66 (20.1%)	352 (55.6%)	298 (60.2%)
Diabetes Mellitus	63 (19.1%)	254 (38.9%)	159 (32.1%)
Congestive Heart Failure	68 (20.2%)	186 (28.3%)	122 (24.6%)
Chronic Kidney Disease ^a			
eGFR ≥60ml/min/1.73m ²	255 (75.2%)	430 (65.5%)	247 (50.2%)
eGFR 30 -59ml/min/1.73m ²	45 (13.3%)	160 (24.4%)	217 (44.1%)
eGFR < 30 ml/min/1.73m ²	39 (11.5%)	217 (44.1%)	28 (5.7%)
Concurrent medications			
Statins ^b	95 (28.2%)	412 (62.7%)	308 (62.2%)
Antiplatelet agents ^c	133 (36.5%)	418 (63.6%)	338 (68.3%)
Amiodarone	17 (5.0%)	76 (11.6%)	62 (12.5%)
Genetic factors ^d			
CYP2C9 *2 variant	39 (13.6%)	94 (16.7%)	75 (17.9%)
CYP2C9 *3 variant	15 (5.2%)	41 (7.3%)	47 (11.2%)
CYP2C9*5 or *6 or *11	8 (2.8%)	8 (1.4%)	3 (0.7%)
VKORC1 (-1639C/T)			
Wild-type	198 (66.9%)	336 (59.1%)	217 (50.1%)
Variant	98 (33.1%)	232 (40.9%)	216 (49.9%)
CYP4F2 variant	90 (32.5%)	193 (35.2%)	170 (41.5%)
rs12777823	101 (36.5%)	186 (34.0%)	152 (37.0%)

Table 2: Warfarin dose requirements by age (<50, 50-70, >70 years) accounting for the effect of genetic and clinical factors

Variable	Effect on Warfarin Dose (95% CI)		
	Dose (mg/day)	% Dose Change	P-value
White male < 50 years ^a	8.1 (7.5 to 8.8)		
50-70 years	7.2 (6.3 to 8.3)	-10.6 (-15.8 to -5.2)	0.0002
> 70 years	7.2 (6.3 to 8.3)	-10.6 (-15.1 to -5.9)	<0.0001
African American	7.6 (6.6 to 8.7)	-6.2 (-11.3 to -0.9)	0.02
Female	7.9 (6.9 to 9.0)	-2.2 (-6.9 to 2.8)	0.39
BMI centered at 25 kg/m ²	9.0 (8.1 to 10)	11.3 (8.7 to 14.0)	<0.0001
Chronic Kidney disease	7.5 (6.7 to 8.5)	-6.8 (-9.9 to -3.6)	<0.0001
Venous thromboembolism	8.4 (7.4 to 9.6)	4.3 (-0.7 to 9.6)	0.09
Congestive Heart Failure	7.6 (6.6 to 8.7)	-6.6 (-11.5 to -1.5)	0.012
Concurrent amiodarone use	6.4 (5.5 to 7.5)	-20.6 (-26.1 to -14.6)	<0.0001
Statin Use	7.8 (6.8 to 8.8)	-4.0 (-8.4 to 0.6)	0.08
<i>CYP2C9</i> *2	6.6 (5.8 to 7.6)	-18.3 (-22.7 to -13.6)	<0.0001
<i>CYP2C9</i> *3	6.8 (4.5 to 6.2)	-34.7 (-39.5 to -29.6)	<0.0001
<i>CYP2C9</i> *5 or *6 or *11	6.0 (5.2 to 8.7)	-16.5 (-29.8 to -0.6)	0.04
<i>VKORC1</i>	8.4 (5.3 to 6.7)	-26.1 (-28.8 to -23.3)	<0.0001
<i>CYP4F2</i>	6.0 (7.4 to 9.5)	3.7 (-0.3 to 7.8)	0.07
rs12777823	7.4 (6.5 to 8.4)	-8.6 (-12.7 to -4.2)	0.0001

Table 3: Influence of age (categorized as <50; 50-70; ≥70 years) on indices of anticoagulation control, and incidence of hemorrhage

Characteristics	Age < 50 (n=341)	Age 50-70 (n=661)	Age >70 (n=496)
PTBR (INR <2)	37.8 ± 28.4	26.6 ± 26.6	24.3 ± 19.8
PTTR (INR 2-3)	44.6 ± 23.8	52.7 ± 55.3	57.2 ± 20.5
PTAR (INR >3)	15.4 ± 17.6	19.2 ± 20.9	17.7 ± 15.9
Number of patients (%) achieving good anticoagulation control			
Poor (PTTR<60)	250 (73.3%)	394 (59.6%)	257 (51.8%)
Good (PTTR≥60<70)	40 (11.7%)	117 (17.7%)	104 (21.0%)
Excellent (PTTR>70)	51 (15.0%)	150 (22.7%)	135 (27.2%)
Major hemorrhage			
Number of events	20	78	75
Follow-up (years)	363.1	925.3	761.5
Incidence (95% CI)	5.5 [3.5, 8.4]	8.4 [6.7, 10.5]	9.8 [7.8, 12.3]

Figure legends

Figure 1a. Percent time spent below, in, and above target INR range of 2.0-3.0 by warfarin users across the three age groups.

Figure 1b. Proportion of patients achieving poor, good, and excellent anticoagulation control by warfarin users across the three age groups.

Figure 1c. Time to major hemorrhage across the three age groups.

Estimated survival curve from Cox proportional hazards model adjusted for race, gender, BMI, hypertension, chronic kidney disease, PTTR (<60% vs. ≥60%), concurrent antiplatelet, amiodarone and statin medications, and *CYP2C9* genotype (note: y axis starts at 0.5)

Figure 1a.




Figure 1b.




Figure 1c.

